The Current State of Potential Therapeutic Modalities for Glioblastoma Multiforme: A Clinical Review

Author(s): Elmira Mohtashami, Negar Shafaei-Bajestani, Hamid Mollazadeh, Seyed Hadi Mousavi, Mohammad Jalili-Nik, Amirhossein Sahebkar*, Amir R. Afshari*

Journal Name: Current Drug Metabolism

Volume 21 , Issue 8 , 2020

Become EABM
Become Reviewer

Abstract:

Glioblastoma multiforme (GBM), as the most lethal brain tumor, continues to be incurable. Considering the high mortality rate of GBM, it is crucial to develop new treatment approaches. Conventional therapies, including maximal surgical resection, radiation therapy, and chemotherapy (typically temozolomide), have not led to significant changes in the survival rates of GBM patients. However, emerging modalities, such as the use of tyrosine kinase inhibitors, mTOR inhibitors, NF-κB modulators, nitrosoureas, and immunotherapeutic agents have shown promising in improving GBM outcomes. In this context, we reviewed the current status of GBM treatment, the efficacy of existing standard therapies in improving disease outcomes, and future therapeutic directions.

Keywords: Glioblastoma multiforme, tyrosine kinase inhibitor, mTOR inhibitor, NF-κB modulator, immunotherapy, nitrosoureas.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 21
ISSUE: 8
Year: 2020
Page: [564 - 578]
Pages: 15
DOI: 10.2174/1389200221666200714101038
Price: $95

Article Metrics

PDF: 9